Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ZEVRA THERAPEUTICS, INC. (ZVRA)

Zevra Q3 revenue rises 45% to $37.8 million; net income $19.2 million

Positive Impact 3 of 5 earnings Written later

Zevra Therapeutics reported third-quarter 2026 revenue, net of $37.8 million, up from $26.1 million a year earlier, and net income of $19.2 million, or $0.26 per diluted share, compared with a net loss of $0.5 million in Q3 2025. Operating expenses rose to $24.1 million from $20.4 million, and the company reported $270.9 million in cash, cash equivalents and investments as of September 30, 2026.

Key points

  • Q3 2026 net revenue of $37.8 million, including $34.0 million from MIPLYFFA, up from $26.1 million in Q3 2025
  • Net income of $19.2 million, or $0.26 per diluted share, versus a net loss of $0.5 million, or $(0.01) per share, in Q3 2025; the quarter included a $5.1 million noncash gain from warrant and CVR liability fair value adjustments
  • Operating expenses of $24.1 million, up from $20.4 million, with SG&A at $19.1 million and R&D at $4.9 million
  • Cash, cash equivalents and investments of $270.9 million as of September 30, 2026; the company hosts a conference call today at 4:30 p.m. ET

The filing

CompanyZEVRA THERAPEUTICS, INC. (ZVRA)
Form8-K, current report
Filed with the SECNov 3, 2026, 4:08 PM ET
Accession number0001434647-26-000085

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.